DelveInsight’s, “Marginal Zone Lymphoma Pipeline Insight 2023” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Marginal Zone Lymphoma pipeline landscape. It covers the Marginal Zone Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Marginal Zone Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Marginal Zone Lymphoma Pipeline Report

• DelveInsight’s Marginal Zone Lymphoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Marginal Zone Lymphoma treatment.
• The leading companies working in the Marginal Zone Lymphoma Market include Incyte Corporation, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Incyte Corporation, Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc, Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc, Celldex Therapeutics, TG Therapeutics, VelosBio Inc., Newave Pharmaceutical Inc, Boryung Pharmaceutical Co., Ltd, Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc., Gamida Cell, BeiGene, Loxo Oncology, and others
• Promising Marginal Zone Lymphoma Pipeline Therapies in the various stages of development include Tafasitamab, Orelabrutinib, EO2463, MIL62, Loncastuximab, NX-2127, LP-168, Zandelisib, BR101801, BP1002, Mosunetuzumab, CLR 131, IBI376, Pirtobrutinib, Zilovertamab vedotin, TG-1801, VAY736, ADI-001, CDX-1140, PSB202, Acalabrutinib, axicabtagene ciloleucel, Obinutuzumab, Cirmtuzumab, Nemtabrutinib, Lenalidomide, IGM-2323, Epcoritamab, GDA-201, BGB-16673,  LOXO-305, and others.
• December 2023: Nurix Therapeutics Inc. announced a study of Phase 1 clinical trials for NX-5948. This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
• December 2023: John Lister announced a study of Phase 2 clinical trials for Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous). This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia.
• December 2023: Fred Hutchinson Cancer Center announced a study of Phase 1 & 2 clinical trials for Cyclophosphamide and Leukapheresis. The purpose of this research is to find the best dose of genetically modified T-cells, to study the safety of this treatment, and to see how well it works in treating patients with B cell non-Hodgkin lymphoma that has come back (relapsed) or did not respond to previous treatment (refractory).
• December 2023: Beigene announced a study of Phase 1 & 2 clinical trials for BGB-10188, Zanubrutinib and Tislelizumab. The purpose of this study is to determine the maximum tolerated dose (MTD), recommended dose for expansion (RDFE), safety and tolerability of BGB-10188 as monotherapy in participants with relapsed/refractory (R/R) mature B-cell malignancies; in combination with zanubrutinib in participants with R/R follicular lymphoma (FL), R/R mantle cell lymphoma (MCL) or R/R diffuse large B-cell lymphoma (DLBCL); and in combination with tislelizumab in participants with advanced solid tumors.

 

Request a sample and discover the recent advances in Marginal Zone Lymphoma Treatment Drugs @ Marginal Zone Lymphoma Pipeline Outlook Report

 

In the Marginal Zone Lymphoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Marginal Zone Lymphoma NDA approvals (if any), and product development activities comprising the technology, Marginal Zone Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Marginal Zone Lymphoma Overview

Marginal zone lymphoma (MZL) is the second most common indolent non-Hodgkin’s lymphoma (iNHL). There are three types of marginal zone lymphomas: the extranodal MZL (EMZL) of mucosa-associated lymphoid tissue (MALT or gastric GALT), the splenic MZL, and the nodal MZL. EMZL can originate at virtually any extranodal site and arises in organs that normally lack lymphoid tissue (eg, stomach, intestine, thyroid, lung, and skin).

 

Find out more about Marginal Zone Lymphoma Therapeutics Assessment @ Marginal Zone Lymphoma Preclinical and Discovery Stage Products

 

Marginal Zone Lymphoma Emerging Drugs Profile

• Tafasitamab: Incyte Corporation
• Amdizalisib (HMPL-689): HUTCHMED
• Orelabrutinib: InnoCare Pharma
• EO2463: Enterome

 

Marginal Zone Lymphoma Pipeline Therapeutics Assessment

There are approx. 50+ key companies that are developing therapies for Marginal Zone Lymphoma. The Marginal Zone Lymphoma companies have their Marginal Zone Lymphoma drug.

 

DelveInsight’s Marginal Zone Lymphoma pipeline report covers around 50+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

 

Marginal Zone Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

 

Marginal Zone Lymphoma Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

 

Learn more about the emerging Marginal Zone Lymphoma Pipeline Therapies @ Marginal Zone Lymphoma Clinical Trials Assessment

 

Scope of the Marginal Zone Lymphoma Pipeline Report

• Coverage- Global
• Marginal Zone Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Marginal Zone Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Marginal Zone Lymphoma Companies- Incyte Corporation, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Incyte Corporation, Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc, Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc, Celldex Therapeutics, TG Therapeutics, VelosBio Inc., Newave Pharmaceutical Inc, Boryung Pharmaceutical Co., Ltd, Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc., Gamida Cell, BeiGene, Loxo Oncology, and others
• Marginal Zone Lymphoma Pipeline Therapies- Tafasitamab, Orelabrutinib, EO2463, MIL62, Loncastuximab, NX-2127, LP-168, Zandelisib, BR101801, BP1002, Mosunetuzumab, CLR 131, IBI376, Pirtobrutinib, Zilovertamab vedotin, TG-1801, VAY736, ADI-001, CDX-1140, PSB202, Acalabrutinib, axicabtagene ciloleucel, Obinutuzumab, Cirmtuzumab, Nemtabrutinib, Lenalidomide, IGM-2323, Epcoritamab, GDA-201, BGB-16673,  LOXO-305, and others.

 

Dive deep into rich insights for new drugs for Marginal Zone Lymphoma Treatment, Visit @ Marginal Zone Lymphoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Marginal Zone Lymphoma Executive Summary
3. Marginal Zone Lymphoma Overview
4. Marginal Zone Lymphoma Pipeline Therapeutics
5. Marginal Zone Lymphoma Pipeline Therapeutic Assessment
6. Marginal Zone Lymphoma – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Tafasitamab: Incyte Corporation
9. Mid Stage Products (Phase II)
10. Orelabrutinib: InnoCare Pharma
11. Early Stage Products (Phase I/II)
12. EO2463: Enterome
13. Preclinical and Discovery Stage Products
14. Drug name: Company name
15. Inactive Products
16. Marginal Zone Lymphoma Key Companies
17. Marginal Zone Lymphoma Key Products
18. Marginal Zone Lymphoma- Unmet Needs
19. Marginal Zone Lymphoma- Market Drivers and Barriers
20. Marginal Zone Lymphoma- Future Perspectives and Conclusion
21. Marginal Zone Lymphoma Analyst Views
22. Marginal Zone Lymphoma Key Companies
23. Appendix

 

For further information on the Marginal Zone Lymphoma Pipeline therapeutics, reach out to Marginal Zone Lymphoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/persistent-epithelial-defect-market